Checkpoint inhibitors in pancreatic cancer
In 2016 pancreatic cancer (PC) moved from 4th[1,2] to 3rd leading cause of cancer death in the US, surpassing breast cancer[3]. PC is projected to be the second leading cause of cancer related death in 2020[4,5]. Over 90% of PC cases develop in the exocrine tissue. Pancreatic adenocarcinomas compromise most of the exocrine tumors and of these the pancreatic ductal adenocarcinoma (PDAC) is the most frequent histological subtype[6]. About half of patients with PC present with distant metastases while approximately a third present with locally advanced disease[7].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Andreas Henriksen, Anne Dyhl-Polk, Inna Chen, Dorte Nielsen Tags: Systematic or Meta-analysis Studies Source Type: research
More News: Adenocarcinoma | Breast Cancer | Cancer | Cancer & Oncology | Pancreas | Pancreatic Cancer | Study